HeartMate II Beats Medical Management In Ambulatory Heart Failure Patients
This article was originally published in The Gray Sheet
Executive Summary
The Thoratec-sponsored ROADMAP non-randomized study favored the HeartMate II ventricular assist device over optimal medical management in a set of patients who are less symptomatic than the majority of current VAD patients. But HeartMate II patients experienced more adverse events including strokes and gastrointestinal bleeds.
You may also be interested in...
Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.